OpenNashPodcasts

Person

Chris Schott

Chris Schott is a speaker who appeared on J.P. Morgan's Making Sense podcast in an episode called "The Growing Appetite for Obesity Drugs," which covered newer GLP-1 weight-loss medicines, their makers and their costs. Schott said about 40% of the U.S. population is obese, and that Novo Nordisk and Eli Lilly lead the field.

He also said patients are losing 20, 30 or even 50 pounds in their first year, and that those who stop the drugs tend to regain most of their weight fairly quickly. On the business side, he said it takes about three years to add manufacturing capacity, and that Amgen and Pfizer trail the two leaders by decades.

1 episodes · 12 quoted claims

Chris Schott says the leading makers of the newer GLP-1 drugs are Novo Nordisk and Eli Lilly.

“It's really two players right now. So it's Novo Nordisk and it's Eli Lilly.”

Making Sense (J.P. Morgan) · 0:03:37

Chris Schott says newer GLP-1 drugs are producing weight loss of 20, 30 or even 50 pounds in patients' first year.

“We're now starting to see patients losing 20, 30, 50 pounds of weight over the first year they're on a medication.”

Making Sense (J.P. Morgan) · 0:04:05

Chris Schott notes the 20% cardiovascular benefit in SELECT came with only 10 to 15% body weight loss, and expects larger benefits from stronger drugs.

“if we have a 20 % benefit for these patients, only losing 10 or 15 % of their body weight”

Making Sense (J.P. Morgan) · 0:06:47

Chris Schott says Novo Nordisk and Eli Lilly have upcoming drugs producing roughly 25% weight loss.

“Novo has drugs coming that's 25%. Lilly's in the same range.”

Making Sense (J.P. Morgan) · 0:07:21

Chris Schott assumes obesity drugs will cost only a few thousand dollars a year once access is broadly available.

“We're assuming these things will only cost a few $1,000 a year when you look out to when access is broadly available.”

Making Sense (J.P. Morgan) · 0:10:50

Chris Schott says it takes about three years from deciding to add manufacturing capacity to having it available.

“the lead time here is about three years from when you decide you need capacity to when you can get it”

Making Sense (J.P. Morgan) · 0:13:34

Chris Schott says Eli Lilly recently added a facility that doubles its capacity for these drugs.

“Lilly just added a facility that doubles their capacity.”

Making Sense (J.P. Morgan) · 0:13:34

Chris Schott expects Eli Lilly's oral obesity drug, now in phase three trials, to report data in 2025 and launch in 2026.

“they're in phase three. It's the last phase of development. We'll see data in 2025. We'll launch the drugs in 2026.”

Making Sense (J.P. Morgan) · 0:14:31

Chris Schott says Amgen and Pfizer are developing rival obesity drugs but that Novo Nordisk and Eli Lilly have decades of head start.

“there's companies like Amgen and Pfizer that are working. But Novo and Lilly have spent decades working on this class of medication.”

Making Sense (J.P. Morgan) · 0:14:56

Chris Schott says patients who stop GLP-1 medications tend to regain most of their weight fairly quickly.

“if you stop taking these medications, the patients tend to regain a majority of their weight fairly quickly”

Making Sense (J.P. Morgan) · 0:18:34

Chris Schott says some Eli Lilly data show about half of diabetic patients on its drug bring their blood sugar back to normal.

“some of the Lilly data, like half the patients who go on these medications get their blood sugar back down to normal”

Making Sense (J.P. Morgan) · 0:22:41